---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-181885"
form_type: "8-K/A"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T04:07:30.672717+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# XOMA completes Generation Bio acquisition; estimates CVR value at $0.81/share

## Summary
- XOMA paid $4.2913 per share cash plus one non-tradeable CVR for Generation Bio; ~70% of shares tendered.
- CVR estimated at $0.81 per share, mainly from net cash above $29M; no value assigned to legacy assets.
- Acquired ~$98M in Section 174 tax deductions and legacy LNP assets; no plans for preclinical development.
- Moderna deal has up to ~$1.8B in milestones; next $7.5M milestone not expected within 12 months.
- XOMA will use commercially reasonable efforts for 2 years to monetize legacy IP for CVR holders.

## SEC filing metadata
- accession: 0001193125-26-181885
- form_type: 8-K/A
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312526181885/0001193125-26-181885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312526181885/d229976d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-181885
- JSON: https://secwatch.observer/filing/0001193125-26-181885.json
- Plain text: https://secwatch.observer/filing/0001193125-26-181885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.